Capecitabine + Epirubicin + AMG 102 + Cisplatin + Placebo
Phase 1/2Completed 0 watching 0 views this week⚡ Active
40
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Esophagogastric Junction Adenocarcinoma
Conditions
Esophagogastric Junction Adenocarcinoma, Gastric Cancer, Esophageal Cancer
Trial Timeline
Feb 1, 2009 → Jun 1, 2013
NCT ID
NCT00719550About Capecitabine + Epirubicin + AMG 102 + Cisplatin + Placebo
Capecitabine + Epirubicin + AMG 102 + Cisplatin + Placebo is a phase 1/2 stage product being developed by Amgen for Esophagogastric Junction Adenocarcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00719550. Target conditions include Esophagogastric Junction Adenocarcinoma, Gastric Cancer, Esophageal Cancer.
Hype Score Breakdown
Clinical
13
Activity
8
Company
9
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00719550 | Phase 1/2 | Completed |
Competing Products
6 competing products in Esophagogastric Junction Adenocarcinoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Trastuzumab deruxtecan + 5FU/LV + Trastuzumab deruxtecan + FLO | Daiichi Sankyo | Phase 1/2 | 41 |
| Pembrolizumab + Trastuzumab + FLOT | Merck | Phase 2 | 52 |
| bevacizumab + capecitabine + cisplatin + Epirubicin + Lapatinib | Roche | Phase 2/3 | 65 |
| Sacituzumab govitecan | Gilead Sciences | Phase 1/2 | 40 |
| regorafenib + nivolumab + FOLFOX chemotherapy with oxaliplatin | Bristol Myers Squibb | Phase 2 | 51 |
| 18F-BMS-986229 Injection + IV 18F-BMS-986229 | Bristol Myers Squibb | Pre-clinical | 22 |